Neither loss of Bik alone, nor combined loss of Bik and Noxa, accelerate murine lymphoma development or render lymphoma cells resistant to DNA damaging drugs

Cell Death and Disease

Volumn 3, Issue 5, 2012, Pages

  Happo, L ^a   Phipson, B ^a,b   Smyth, G K ^a,b   Strasser, A ^a,b   Scott, C L ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Apoptosis; Bcl 2 family; BH3 only; Bik; Myc; Noxa

Indexed keywords

BH3 PROTEIN; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; ANTINEOPLASTIC AGENT; BIKLK PROTEIN, MOUSE; ETOPOSIDE; MITOCHONDRIAL PROTEIN; MYC PROTEIN; PMAIP1 PROTEIN, MOUSE; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DISEASE COURSE; DNA DAMAGE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA; LYMPHOMA CELL; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; ANIMAL; C57BL MOUSE; DRUG EFFECT; DRUG RESISTANCE; FEMALE; GENETICS; MALE; METABOLISM; MOUSE MUTANT; PATHOLOGY; PROTEIN BINDING; TUMOR CELL LINE;

MURINAE; MUS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; LYMPHOMA; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOCHONDRIAL PROTEINS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84861560772     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.42     Document Type: Article

References (39)

1. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26: 1324-1337.
2. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393-403.
3. Chipuk JE, Green DR. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol 2008; 18: 157-164.
4. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007; 315: 856-859.
5. Hegde R, Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Alnemri ES. Blk a BH3-containing mouse protein that interacts with Bcl-2 and Bcl-xL, is a potent death agonist. J Biol Chem 1998; 273: 7783-7786.
6. Boyd JM, Gallo GJ, Elangovan B, Houghton AB, Malstrom S, Avery BJ et al. Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. Oncogene 1995; 11: 1921-1928.
7. Coultas L, Bouillet P, Stanley EG, Brodnicki TC, Adams JM, Strasser A. Proapoptotic BH3-only Bcl-2 family member Bik/Blk/Nbk is expressed in hemopoietic and endothelial cells but is redundant for their programmed death. Mol Cell Biol 2004; 24: 1570-1581.
8. Chinnadurai G, Vijayalingam S, Rashmi R. BIK the founding member of the BH3-only family proteins: mechanisms of cell death and role in cancer and pathogenic processes. Oncogene 2008; 27(Suppl 1): S20-S29.
9. Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM. The Em-myc transgenic mouse: a model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med 1988; 167: 353-371.
10. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985; 318: 533-538.
11. Han J, Sabbatini P, White E. Induction of apoptosis by human Nbk/Bik, a BH3-containing protein that interacts with E1B 19 K. Mol Cell Biol 1996; 16: 5857-5864.
12. Germain M, Mathai JP, Shore GC. BH-3-only BIK functions at the endoplasmic reticulum to stimulate cytochrome c release from mitochondria. J Biol Chem 2002; 277: 18053-18060.
13. Mathai JP, Germain M, Shore GC. BH3-only BIK regulates BAX,BAK-dependent release of Ca2 + from endoplasmic reticulum stores and mitochondrial apoptosis during stressinduced cell death. J Biol Chem 2005; 280: 23829-23836.
14. Gillissen B, Essmann F, Graupner V, Starck L, Radetzki S, Dorken B et al. Induction of cell death by the BH3-only Bcl-2 homolog Nbk/Bik is mediated by an entirely Bax-dependent mitochondrial pathway. EMBO J 2003; 22: 3580-3590.
15. Germain M, Mathai JP, McBride HM, Shore GC. Endoplasmic reticulum BIK initiates DRP1-regulated remodelling of mitochondrial cristae during apoptosis. EMBO J 2005; 24: 1546-1556.
16. Tong Y, Yang Q, Vater C, Venkatesh LK, Custeau D, Chittenden T et al. The pro-apoptotic protein, Bik, exhibits potent antitumor activity that is dependent on its BH3 domain. Mol Cancer Ther 2001; 1: 95-102.
17. Mathai JP, Germain M, Marcellus RC, Shore GC. Induction and endoplasmic reticulum location of BIK/NBK in response to apoptotic signaling by E1A and p53. Oncogene 2002; 21: 2534-2544.
18. Hur J, Bell DW, Dean KL, Coser KR, Hilario PC, Okimoto RA et al. Regulation of expression of BIK proapoptotic protein in human breast cancer cells: p53-dependent induction of BIK mRNA by fulvestrant and proteasomal degradation of BIK protein. Cancer Res 2006; 66: 10153-10161.
19. Paquet C, Schmitt E, Beauchemin M, Bertrand R. Activation of multidomain and BH3-only pro-apoptotic Bcl-2 family members in p53-defective cells. Apoptosis 2004; 9: 815-831.
20. Real PJ, Sanz C, Gutierrez O, Pipaon C, Zubiaga AM, Fernandez-Luna JL. Transcriptional activation of the proapoptotic bik gene by E2F proteins in cancer cells. FEBS Lett 2006; 580: 5905-5909.
21. Happo L, Cragg MS, Phipson B, Haga JM, Jansen ES, Herold MJ et al. Maximal killing of lymphoma cells by DNA-damage inducing therapy requires not only the p53 targets Puma and Noxa but also Bim. Blood 2010; 116: 5256-5267.
22. Michalak EM, Jansen ES, Happo L, Cragg MS, Tai L, Smyth GK et al. Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis. Cell Death Differ 2009; 16: 684-696.
23. Egle A, Harris AW, Bouillet P, Cory S. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci USA 2004; 101: 6164-6169.
24. Garrison SP, Jeffers JR, Yang C, Nilsson JA, Hall MA, Rehg JE et al. Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis. Mol Cell Biol 2008; 28: 5391-5402.
25. Frenzel A, Labi V, Chmelewskij W, Ploner C, Geley S, Fiegl H et al. Suppression of B-cell lymphomagenesis by the BH3-only proteins Bmf and Bad. Blood 2010; 115: 995-1005.
26. Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR et al. BH3 Domains of BH3-Only Proteins Differentially Regulate Bax-Mediated Mitochondrial Membrane Permeabilization Both Directly and Indirectly. Mol Cell 2005; 17: 525-535.
27. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARFMdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999; 13: 2658-2669.
28. Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo C et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 2005; 436: 807-811.
29. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001; 2: 731-737.
30. Bissonnette RP, Echeverri F, Mahboubi A, Green DR. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 1992; 359: 552-554.
31. Fanidi A, Harrington EA, Evan GI. Cooperative interaction between c-myc and bcl-2 protooncogenes. Nature 1992; 359: 554-556.
32. Strasser A, Harris AW, Bath ML, Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990; 348: 331-333.
33. Merino D, Strasser A, Bouillet P. Bim must be able to engage all pro-survival Bcl-2 family members for efficient tumor suppression. Oncogene 2011; e-pub ahead of print 14 November 2011; doi:10.1038/onc.2011.500.
34. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 1998; 12: 2424-2433.
35. Verma S, Budarf ML, Emanuel BS, Chinnadurai G. Structural analysis of the human proapoptotic gene Bik: chromosomal localization, genomic organization and localization of promoter sequences. Gene 2000; 254: 157-162.
36. Villunger A, Michalak EM, Coultas L, Mü llauer F, Böck G, Ausserlechner MJ et al. p53-and drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa. Science 2003; 302: 1036-1038.
37. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994; 4: 1-7.
38. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 1999; 13: 2670-2677.
39. Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, Lowe SW. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 2002; 1: 289-298.